Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07370584 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults
A Phase 1 study of Safety Study, sponsored by iVeena Delivery Systems.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT07370584: Recruiting Phase 1 study of Safety Study, sponsored by iVeena Delivery Systems.
NCT07370584 is a Phase 1 study of Safety Study that is actively recruiting participants, run by iVeena Delivery Systems. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07370584, a Phase 1 study of Safety Study, is actively recruiting participants, sponsored by iVeena Delivery Systems.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this trial is to determine the safety of IVMED-85 eye drops in healthy adult subjects. Participants will be assigned to either the active or vehicle eyedrop group. The participants will receive eye drops twice daily for 6 weeks. Participants will not know which eyedrop they are taking.
Primary Outcome
Change from baseline in corrected distance visual acuity (CDVA) with Early Treatment Diabetic Retinopathy Study (ETDRS) in the study eye (SE) at all post-baseline visits. The change in ETDRS scores will be recorded as logMAR scores and letters missed on the eye chart. A logMAR of 0.0 corresponds to 20/20 vision; higher values indicate greater myopia (near-sighted), and lower values indicate greater hyperopia (far-sighted) .
Conditions Studied
Interventions
- DRUG IVMED-85 ophthalmic solution
- DRUG Vehicle Ophthalmic Solution
Study Locations (1)
Tennessee
- Total Eye Care, P.A. - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-02-04 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What NCT07370584 shows while recruiting
NCT07370584 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Safety Study appearing as the primary indexed condition, and to 2 interventions - of which IVMED-85 ophthalmic solution is the first listed.
NCT07370584 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT07370584 about?
NCT07370584 is a clinical study titled "A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults". The purpose of this trial is to determine the safety of IVMED-85 eye drops in healthy adult subjects. Participants will be assigned to either the active or vehicle eyedrop group. The participants will receive eye drops twice daily for 6 weeks. Participants will not know which eyedrop they are taking...
What is the current status of trial NCT07370584?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2026-02-04. Estimated completion is 2026-07.
What conditions does trial NCT07370584 study?
This clinical trial studies the following conditions: Safety Study.
What interventions are being tested in trial NCT07370584?
The interventions under investigation include: IVMED-85 ophthalmic solution (DRUG), Vehicle Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT07370584?
This trial is sponsored by iVeena Delivery Systems, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07370584 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07370584's enrollment target sits among peer trials
36 1211th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI